2-amino-1,3-propanediol compound and immunosuppressant 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
EP0627406 A1 1994-12-07 [EP-627406]EP0627406 A4 1995-04-12 [EP-627406]EP0627406 B1 1998-10-28 [EP-627406] / 1994-12-071995-04-121998-10-28
申请号/申请日
1993EP-0923035 / 1993-10-18
发明人
FUJITA TETSURO;SASAKI SHIGEO;YONETA MASAHIKO;MISHINA TADASHI;ADACHI KUNITOMO;CHIBA KENJI;
申请人
YOSHITOMI PHARMACEUTICAL;
主分类号
IPC分类号
A01N-033/02A01N-043/40A01N-043/60A01N-057/00C07C-215/10C07C-215/18C07C-215/20C07C-215/24C07C-215/26C07C-215/28C07C-215/34C07C-215/42C07C-215/54C07C-215/56C07C-215/68C07C-217/28C07C-217/30C07C-217/34C07C-217/48C07C-217/52C07C-217/64C07
摘要
(EP-627406) A 2-amino-1,3-propanediol compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, and an immunosuppressant containing the same as the active ingredient.  In said formula R represents optionally substituted linear or branched carbon chain, optionally substituted aryl or optionally substituted cycloalkyl; and R<2>, R<3>, R<4> and R<5>, which may be the same or different from one another, represent each hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl.  The compound is immunodepressant and useful as an inhibitor against rejection in organ or bone marrow transplantation, as a preventive or remedy for autoimmune diseases and so forth, or a reagent in the medical and pharmaceutical fields. <CHEM>
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
1992JP-0283281 1992-10-21 1993JP-0179427 1993-07-20 1993WO-JP01515 1993-10-18
主权利要求
(EP-627406)  1. A 2-amino-1,3-propanediol compound of the formula (see diagramm 1 page 448) wherein R is an optionally substituted straight- or branched carbons chain which may have, in the chain, a bond, a hetero atom or a group selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, carbonyl, optionally substituted arylene, optionally substituted cycloalkylene, optionally substituted heteroarylene and an alicycle thereof, and which may be substituted, at the chain end thereof, by a double bond, a triple bond, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl or an alicycle thereof;  an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted heteroaryl or an alicycle thereof;  and R**2, R**3, R**4 and R**5   are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, or R**4 and R**5 may be bonded to form an alkylene chain which may be substituted by alkyl, aryl or aralkyl;   wherein the optionally substituted straight- or branched carbon chain may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxyimino, hydroxy, carboxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkyl, optionally substituted heteroaryl and an alicycle thereof;  the aforementioned optionally substituted arylene, optionally substituted cycloalkylene, optionally substituted heteroarylene and an alicycle thereof may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxy and carboxy;  and the optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkyl, optionally substituted heteroaryl and an alicycle thereof may have a substituent selected from the group consisting of alkyl, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxy and carboxy;   provided that when R is C1-C5 alkyl, the alkyl should be  substituted and when R is furylmethyl, phenylmethyl or phenylmethyl substituted by lower alkyl, lower alkoxy, chloro, hydroxy or amino, one of R**2 and R**3 is not methyl or ethyl;  or a pharmaceutically acceptable salt thereof.  2. A 2-amino-1,3-propanediol compound of Claim 1, having the formula (see diagramm 1 page 450) wherein R**1 is an optionally substituted straight- or branched carbon chain which may have, in the chain, a bond, a hetero atom or a group selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, carbonyl, optionally substituted arylene, optionally substituted cycloalkylene, optionally substituted heteroarylene and an alicycle thereof, and which may be substituted, at the chain end (omega -position) thereof, by a double bond, a triple bond, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl or an alicycle thereof;  an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted heteroaryl or an alicycle thereof;  and R**2, R**3, R**4 and R**5    are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, or R**4 and R**5 may be bonded to form an alkylene chain which may be substituted by alkyl, aryl or aralkyl;  wherein the optionally substituted straight- or branched carbon chain may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxyimino, hydroxy, carboxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkyl, optionally substituted heteroaryl and an alicycle thereof;  and the aforementioned optionally substituted arylene, optionally substituted cycloalkylene, optionally substituted heteroarylene, an alicycle thereof, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkyl, optionally substituted heteroaryl and an alicycle thereof may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxy and carboxy;   provided that when R**1 is C1-C4 alkyl, the alkyl should be substituted and when R**1 is furyl, phenyl or phenyl substituted  by lower alkyl, lower alkoxy, chloro, hydroxy or amino, one of R**2 and R**3 is not methyl or ethyl;  or a pharmaceutically acceptable salt thereof.  3. A 2-amino-1,3-propanediol compound of Claim 1 or 2, having the formula (see diagramm 1 page 452) wherein R**1a is an optionally substituted straight- or branched carbon chain which may have, in the chain, a bond, a hetero atom or a group selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, carbonyl, optionally substituted phenylene and optionally substituted cycloalkylene;  an optionally substituted phenyl or an optionally substituted cycloalkyl;  and R**2a, R**3a, R**4a and R**5a   are the same or different and each is a hydrogen, an alkyl, an acyl or an alkoxycarbonyl;  wherein the optionally substituted phenyl and optionally substituted cycloalkyl may have a substituent selected from the group consisting of optionally substituted straight- or branched carbon chain which may have, in the chain, a bond, a hetero atom or a group selected from the group consisting of a  double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, carbonyl, optionally substituted phenylene and optionally substituted cycloalkylene;  alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, nitro, halogen, amino, hydroxy, carboxy, optionally substituted phenyl, optionally substituted phenoxy and optionally substituted cycloalkyl;  the optionally substituted carbon chain may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, nitro, halogen, amino, hydroxy, carboxy, optionally substituted phenyl, optionally substituted phenoxy and optionally substituted cycloalkyl;  and the aforementioned optionally substituted phenylene, optionally substituted cycloalkylene, optionally substituted phenyl, optionally substituted phenoxy and optionally substituted cycloalkyl may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, nitro, halogen, amino, hydroxy and carboxy;   provided that when R**1a is C1-C4 alkyl, the alkyl should be substituted and when R**1a is furyl, phenyl or phenyl substituted  by lower alkyl, lower alkoxy, chloro, hydroxy or amino, one of R**2a and R**3a is not methyl or ethyl;  or a pharmaceutically acceptable salt thereof.  4. A 2-amino-1,3-propanediol compound of Claim 3, having the formula (see diagramm 1 page 454) wherein R**1b is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted phenyl or an optionally substituted cycloalkyl, and R**2b, R**3b, R**4b and R**5b   are the same or different and each is a hydrogen, an alkyl or an acyl;  wherein the optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy, carboxy, optionally substituted phenyl and optionally substituted cycloalkyl;  and the aforementioned optionally substituted phenyl and optionally substituted cycloalkyl may have 1 to 3 substituents selected from the group consisting of  alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, nitro, halogen, amino, hydroxy and carboxy;  provided that when R**1b is C1-C4 alkyl, the alkyl should be substituted and when R**1b is furyl, phenyl or phenyl substituted by lower alkyl, lower alkoxy, chloro, hydroxy or amino, one of R**2b and R**3b is not methyl or ethyl;  or a pharmaceutically acceptable salt thereof.  5. A 2-amino-1,3-propanediol compound of any one of Claims 1, 2, 3 and 4, having the formula (see diagramm 1 page 455) wherein Ra is a straight- or branched chain alkyl having 12 to 22 carbon atoms, which may have, in the chain, a bond or a hetero atom selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, and which may have, as a substituent, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxyimino, hydroxy or carboxy, and  R**2b, R**3b, R**4b and R**5b   are the same or different and each is a hydrogen, an alkyl or an acyl;  or a pharmaceutically acceptable salt thereof.  6. A 2-amino-1,3-propanediol compound of Claim 5, having the formula (see diagramm 1 page 456) wherein Rb is a straight- or branched chain alkyl having 13 to 20 carbon atoms, which may have, in the chain, an oxygen atom and which may have, as a substituent, nitro, halogen, amino, hydroxy or carboxy, and R**2c and R**3c   are the same or different and each is a hydrogen or an alkyl, or a pharmaceutically acceptable salt thereof.  7. A 2-amino-1,3-propanediol compound of Claim 5 or 6, having the formula (see diagramm 2 page 456) wherein Rc is a straight- or branched chain alkyl having 13 to 20 carbon atoms or a straight- or branched chain alkyl having 13 to 20 carbon atoms which is substituted by  halogen, or a pharmaceutically acceptable salt thereof.  8. A 2-amino-1,3-propanediol compound of any one of Claims 5, 6 and 7, which is selected from the group consisting of  2-amino-2-tridecyl-1,3-propanediol,  2-amino-2-tetradecyl-1,3-propanediol,  2-amino-2-pentadecyl-1,3-propanediol,  2-amino-2-hexadecyl-1,3-propanediol,  2-amino-2-heptadecyl-1,3-propanediol,  2-amino-2-octadecyl-1,3-propanediol,  2-amino-2-nonadecyl-1,3-propanediol,  2-amino-2-icosyl-1,3-propanediol,  2-amino-2-(12-fluorododecyl)-1,3-propanediol and  2-amino-2-(14-fluorotetradecyl)-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  9. A 2-amino-1,3-propanediol compound of any one of Claims 1, 2, 3 and 4, having the formula (see diagramm 1 page 457) wherein Rd is a phenylalkyl, a substituted phenylalkyl, a cycloalkylalkyl, a substituted cycloalkylalkyl, a heteroarylalkyl, a substituted heteroarylalkyl, a heterocyclic alkyl or a substituted heterocyclic alkyl, wherein the alkyl moiety may have, in the carbon chain, a bond or a hetero atom selected from the group consisting of a double  bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, and may have, as a substituent, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy or carboxy;  and the substituted phenylalkyl, substituted cycloalkylalkyl, substituted heteroarylalkyl and substituted heterocyclic alkyl may have a substituent selected from the group consisting of alkyl, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, haloaralkyloxy, aralkyloxyalkyl, phenoxyalkyl, phenoxyalkoxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxy and carboxy;  or a pharmaceutically acceptable salt thereof.  10. A 2-amino-1,3-propanediol compound of Claim 9, having the formula (see diagramm 1 page 458) wherein Re is a phenylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms;  a phenylalkyl which may be substituted by a straight- or branched chain C6-C20 alkyl optionally substituted by  halogen, a straight- or branched chain C6-C20 alkoxy optionally substituted by halogen, a straight- or branched chain C6-C20 alkenyloxy, phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl;  a cycloalkylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms;  a cycloalkylalkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  a heteroarylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms;  a heteroarylalkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  a heterocyclic alkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms, or a heterocyclic alkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  wherein the alkyl moiety may have, in the carbon chain, a bond or a hetero atom selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, and may have, as a substituent, alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy or carboxy;  or a pharmaceutically acceptable salt thereof.  11. A 2-amino-1,3-propanediol compound of Claim 9 or 10, having  the formula (see diagramm 1 page 460) wherein Rf is a phenylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms which may have, in the carbon chain, one or two oxygen atoms;  a phenylalkyl which may be substituted by a straight- or branched chain C6-C20 alkyl optionally substituted by halogen, a straight- or branched chain C6-C20 alkoxy optionally substituted by halogen, a straight- or branched chain C6-C20 alkenyloxy, phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl;  a cycloalkylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms which may have, in the carbon chain, one or two oxygen atoms;  a cycloalkylalkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  a heteroarylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms which may have, in the carbon chain, one or two oxygen atoms;  a heteroarylalkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  a heterocyclic alkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms  which may have, in the carbon chain, one or two oxygen atoms, or a heterocyclic alkyl substituted by a straight- or branched chain alkyl having 6 to 20 carbon atoms;  wherein the alkyl moiety may have, in the carbon chain, a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, nitro, halogen, amino, hydroxy and carboxy;  or a pharmaceutically acceptable salt thereof.  12. A 2-amino-1,3-propanediol compound of any one of Claims 9, 10 and 11, having the formula (see diagramm 1 page 461) wherein Rg is a phenylalkyl wherein the alkyl moiety is a straight- or branched chain having 6 to 20 carbon atoms which may have, in the carbon chain, one or two oxygen atoms;  a phenylalkyl which may be substituted by a straight- or branched chain C6-C14 alkyl optionally substituted by halogen, a straight- or branched chain C6-C14 alkoxy optionally substituted by halogen, a straight- or branched chain C6-C14 alkenyloxy, phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl;  a cycloalkylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms;  a cycloalkylalkyl substituted by  a straight- or branched chain alkyl having 6 to 14 carbon atoms;  a heteroarylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms;  a heteroarylalkyl substituted by a straight- or branched chain alkyl having 6 to 14 carbon atoms;  a heterocyclic alkyl wherein the alkyl moiety has 6 to 20 carbon atoms, or a heterocyclic alkyl substituted by a straight- or branched chain alkyl having 6 to 14 carbon atoms;  or a pharmaceutically acceptable salt thereof.  13. A 2-amino-1,3-propanediol compound of Claim 12, having the formula (see diagramm 1 page 462) wherein Rh is a phenylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms, a phenylalkoxyalkyl wherein the alkyl moiety and alkoxy moiety have 6 to 20 carbon atoms in total, a phenoxyalkyl wherein the alkyl moiety has 6 to 20 carbon atoms or a phenoxyalkoxyalkyl wherein the alkyl moiety and alkoxy moiety have 6 to 20 carbon atoms in total, or a pharmaceutically acceptable salt thereof.  14. A 2-amino-1,3-propanediol compound of Claim 13, which is selected from the group consisting of  2-amino-2-(8-phenyloctyl )-1,3-propanediol,  2-amino-2-(9-phenylnonyl)-1,3-propanediol,   2-amino-2-(10-phenyldecyl)-1,3-propanediol,  2-amino-2-(11-phenylundecyl)-1,3-propanediol,  2-amino-2-(12-phenyldodecyl)-1,3-propanediol,  2-amino-2-(13-phenyltridecyl)-1,3-propanediol,  2-amino-2-(14-phenyltetradecyl)-1,3-propanediol,  2-amino-2-(15-phenylpentadecyl)-1,3-propanediol,  2-amino-2-(16-phenylhexadecyl)-1,3-propanediol,  2-amino-2-[6-(8-phenyloctyloxy)hexyl]-1,3-propanediol,  2-amino-2-(8-phenylmethyloxyoctyl)-1,3-propanediol,  2-amino-2-(9-phenoxynonyl)-1,3-propanediol,  2-amino-2-(12-phenoxydodecyl)-1,3-propanediol and  2-amino-2-[6-(2-phenoxyethyloxy)hexyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  15. A 2-amino-1,3-propanediol compound of Claim 13, which is selected from the group consisting of  2-amino-2-(10-phenyldecyl)-1,3-propanediol,  2-amino-2-(13-phenyltridecyl)-1,3-propanediol,  2-amino-2-[6-(8-phenyloctyloxy)hexyl]-1,3-propanediol,  2-amino-2-(8-phenylmethyloxyoctyl)-1,3-propanediol,  2-amino-2-(9-phenoxynonyl)-1,3-propanediol,  2-Amino-2-(12-phenoxydodecyl)-1,3-propanediol and  2-amino-2-[6-(2-phenoxyethyloxy)hexyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  16. A 2-amino-1,3-propanediol compound of Claim 12, having the formula  (see diagramm 1 page 464) wherein Ri is a phenylalkyl substituted by a straight- or branched chain C6-C14 alkyl optionally substituted by halogen, a straight- or branched chain C6-C14 alkoxy optionally substituted by halogen or a straight- or branched chain C6-C14 alkenyloxy, wherein the alkyl moiety of phenylalkyl may be substituted by hydroxy, or a pharmaceutically acceptable salt thereof.  17. A 2-amino-1,3-propanediol compound of Claim 16, having the formula (see diagramm 2 page 464) wherein Rj is a phenylalkyl substituted by a straight- or branched chain C6-C14 alkyl optionally substituted by halogen, a straight- or branched chain C6-C14 alkoxy optionally substituted by halogen or a straight- or branched chain C6-C14 alkenyloxy, wherein the alkyl moiety is a C2-C6 alkyl optionally substituted by hydroxy, or a pharmaceutically acceptable salt thereof.  18. A 2-amino-1,3-propanediol compound of Claim 16 or 17, which is selected from the group consisting of   2-amino-2-[2-(4-heptylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-nonylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-decylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-undecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-dodecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-tridecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-tetradecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-hexyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-heptyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-octyloxyphenyl)ethyl)-1,3-propanediol,  2-amino-2-[2-(4-nonyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-decyloxyphenyl)ethyl]-1,3-propanediol,,  2-amino-2-[2-(4-undecyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-dodecyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-tridecyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(8-fluorooctyl)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(12-fluorododecyl)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(7-fluoroheptyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(11-fluoroundecyloxy)phenyl)ethyl]-1,3-propanediol and  2-amino-2-[2-(4-(7-octenyloxy)phenyl)ethyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  19. A 2-amino-1,3-propanediol compound of Claim 16 or 17, which is selected from the group consisting of  2-amino-2-[2-(4-heptylphenyl)ethyl]-1,3-propanediol,   2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-nonylphenyl)ethyl]-1,3-propanediol,  2amino-2-[2-(4-decylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-undecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-dodecylphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-heptyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-octyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-nonyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-undecyloxyphenyl)ethyl]-1,3-propanediol and  2-amino-2-[2-(4-(7-octenyloxy)phenyl)ethyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  20. A 2-amino-1,3-propanediol compound of Claim 12, having the formula (see diagramm 1 page 466) wherein Rk is a phenylalkyl substituted by phenylalkoxy, halophenylalkoxy, phenylalkoxyalkyl, phenoxyalkoxy or phenoxyalkyl, or a pharmaceutically acceptable salt thereof.  21. A 2-amino-1,3-propanediol compound of Claim 20, having the formula (see diagramm 2 page 466) wherein  Rl is a phenylalkyl substituted by phenylalkoxy wherein the alkoxy moiety has 2 to 8 carbon atoms, halophenylalkoxy wherein the alkoxy moiety has 2 to 8 carbon atoms, phenylalkoxyalkyl wherein the alkoxy moiety and alkyl moiety have 2 to 8 carbon atoms in total, phenoxyalkoxy wherein the alkoxy moiety has 2 to 8 carbon atoms or phenoxyalkyl wherein the alkyl moiety has 2 to 8 carbon atoms, where the alkyl moiety has 2 to 6 carbon atoms, or a pharmaceutically acceptable salt thereof.  22. A 2-amino-1,3-propanediol compound of Claim 20 or 21, which is selected from the group consisting of  2-amino-2-[2-(4-phenylmethyloxyphenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(2-phenylethyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(3-phenylpropyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(4-phenylbutyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(5-phenylpentyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(6-phenylhexyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(7-phenylheptyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(8-phenyloctyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[4-(6-(4-fluorophenyl)hexyloxy)phenyl)ethyl]-1,3-propanediol, 2-amino-2-[2-(4-(5-phenylpentyloxymethyl)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(4-phenoxybutyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(5-phenoxypentyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(6-phenoxyhexyloxy)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(7-phenoxyheptyloxy)phenyl)ethyl]-1,3-propanediol,   2-amino-2-[2-(4-(4-phenoxybutyl)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(5-phenoxypentyl)phenyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-(6-phenoxyhexyl)phenyl))ethyl]-1,3-propanediol, and  2-amino-2-[2-(4-(7-phenoxyheptyl)phenyl)ethyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  23. A 2-amino-1,3-propanediol compound of Claim20 or 21, which is selected from the group consisting of 2-amino-2-[2-(4-(6-phenylhexyloxy)phenyl)ethyl]-1,3-propanediol and 2-amino-2-[2-(4-(5-phenylpentyloxymethyl)phenyl))ethyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  24. A 2-amino-1,3-propanediol compound of Claim 12, having the formula (see diagramm 1 page 468) wherein Rm is an alkyl-substituted cycloalkylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms in total, or a pharmaceutically acceptable salt thereof.  25. A 2-amino-1,3-propanediol compound of Claim 24, which is selected from the group consisting of  2-amino-2-[3-(4-heptylcyclohexyl)propyl]-1,3-propanediol,  2-amino-2-[4-(4-butylcyclohexyl)butyl]-1,3-propanediol,  2-amino-2-[2-(4-octylcyclohexyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(4-nonylcyclohexyl))ethyl]-1,3-propanediol and  2-amino-2-[2-(4-dodecylcyclohexyl))ethyl]-1,3-propanediol, or a  pharmaceutically acceptable salt thereof.  26. A 2-amino-1,3-propanediol compound of Claim 12, having the formula (see diagramm 1 page 469) wherein Rn is a 1-alkyl-substituted piperidin-4-ylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms in total, or a pharmaceutically acceptable salt thereof.  27. A 2-amino-1,3-propanediol compound of Claim 26, which is selected from the group consisting of 2-amino-2-[2-(1-octylpiperidin-4-yl)ethyl]-1,3-propanediol, and 2-amino-2-[2-(1-dodecylpiperidin-4-yl)ethyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  28. A 2-amino-1,3-propanediol compound of Claim 12, having the formula (see diagramm 2 page 469) wherein Ro is a thienylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms, an alkyl-substituted thienylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms in total, a pyridylalkyl wherein the alkyl moiety has 6 to 20 carbon atoms or an alkyl-substituted pyridylalkyl wherein the  alkyl moiety has 6 to 20 carbon atoms in total, or a pharmaceutically acceptable salt thereof.  29. A 2-amino-1,3-propanediol compound of Claim 28, which is selected from the group consisting of  2-amino-2-[2-(5-octyl-2-thienyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(5-nonyl-2-thienyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(5-decyl-2-thienyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(5-dodecyl-2-thienyl)ethyl]-1,3-propanediol,  2-amino-2-[13-(2-thienyl)tridecyl]-1,3-propanediol,  2-amino-2-[2-(5-octyl-2-pyridyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(5-decyl-2-pyridyl)ethyl]-1,3-propanediol,  2-amio-2-[13-(2-pyridyl)tridecyl]-1,3-propanediol,  2-amino-2-[2-(2-octyl-5-pyridyl)ethyl]-1,3-propanediol,  2-amino-2-[2-(2-decyl-5-pyridyl)ethyl]-1,3-propanediol and  2-amino-2-[13-(3-pyridyl)tridecyl]-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  30. A 2-amino-1,3-propanediol compound of Claim 1 or 2, having the formula (see diagramm 1 page 470) wherein Rp is a phenyl substituted by C6-C18 alkyl, a cycloalkyl, a heteroaryl or a heterocycle, or a pharmaceutically acceptable salt thereof.  31. A 2-amino-1,3-propanediol compound of Claim 30, having the  formula (see diagramm 1 page 471) wherein Rq is a phenyl substituted by C6-C18 alkyl, or a pharmaceutically acceptable salt thereof.  32. A 2-amino-1,3-propanediol compound of Claim 30 or 31, which is selected from the group consisting of  2-amino-2-(4-decylphenyl)-1,3-propanediol,  2-amino-2-(4-dodecylphenyl)-1,3-propanediol,  2-amino-2-(4-tetradecylphenyl)-1,3-propanediol and  2-amino-2-(4-hexadecylphenyl)-1,3-propanediol, or a pharmaceutically acceptable salt thereof.  33. A 2-amino-1,3-propanediol compound of Claim 1 or 2, having the formula (see diagramm 2 page 471) wherein R**1 is an optionally substituted straight- or branched carbon chain which may have, in the chain, a bond, a hetero atom or a group selected from the group consisting of a double bond, a triple bond, oxygen, sulfur, sulfinyl, sulfonyl, -N(R**6)- where R**6 is hydrogen, alkyl, aralkyl, acyl or alkoxycarbonyl, and carbonyl, optionally substituted  arylene, optionally substituted cycloalkylene, optionally substituted heteroarylene and an alicycle thereof, and which may be substituted, at the chain end (omega -position) thereof, by a double bond, a triple bond, optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroaryl or an alicycle thereof, an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted heteroaryl or an alicycle thereof, and R**2a, R**3a, R**4a and R**5a   are the same or different and each is a hydrogen, an alkyl, an acyl or an alkoxycarbonyl;  wherein the optionally substituted straight- or branched carbon chain may have a substituent selected from the group consisting of alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, alkylenedioxy, acyl, alkylamino, alkylthio, acylamino, alkoxycarbonyl, alkoxycarbonylamino, acyloxy, alkylcarbamoyl, haloalkyl, haloalkoxy, nitro, halogen, amino, hydroxyimino, hydroxy, carboxy, optionally substituted aryl, optionally substituted arylo(...)
法律状态
(EP-627406) LEGAL DETAILS FOR EP0627406  Actual or expected expiration date=2013-10-18    Legal state=DEAD    Status=EXPIRED     Event publication date=1993-10-18  Event code=EP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=EP EP93923035  Application date=1993-10-18  Standardized application number=1993EP-0923035     Event publication date=1994-12-07  Event code=EP/A1  Event type=Examination events  Application published with search report  Publication country=EP  Publication number=EP0627406  Publication stage Code=A1  Publication date=1994-12-07  Standardized publication number=EP-627406     Event publication date=1994-12-07  Event code=EP/17P  Event indicator=Pos  Event type=Examination events  Request for examination filed Pruefungsantrag gestellt  Effective date of the event=1994-06-16     Event publication date=1994-12-07  Event code=EP/AK  Event indicator=Pos  Event type=Designated states  Designated contracting states: Benannte vertragsstaaten AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE    Event publication date=1995-04-12  Event code=EP/A4  Event indicator=Pos  Event type=Examination events  Supplementary search report Ergaenzender recherchenbericht  Publication country=EP  Publication number=EP0627406  Publication stage Code=A4  Publication date=1995-04-12  Standardized publication number=EP-627406     Event publication date=1995-04-12  Event code=EP/A4  Event indicator=Pos  Event type=Administrative notifications  Supplementary search report Despatch of supplementary search report    Event publication date=1995-04-12  Event code=EP/AK  Event indicator=Pos  Event type=Designated states  Designated contracting states: Benannte vertragsstaaten AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE    Event publication date=1996-09-11  Event code=EP/17Q  Event indicator=Pos  Event type=Examination events  First examination report Erster pruefungsbescheid  Effective date of the event=1996-07-30     Event publication date=1998-10-28  Event code=EP/B1  Event indicator=Pos  Event type=Event indicating In Force  Patent specification  Publication country=EP  Publication number=EP0627406  Publication stage Code=B1  Publication date=1998-10-28  Standardized publication number=EP-627406     Event publication date=1998-10-28  Event code=EP/AK  Event indicator=Pos  Event type=Designated states  Designated contracting states: Benannte vertragsstaaten AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE    Event publication date=1998-12-02  Event code=EP/K1C1  Event type=Corrections  Correction of patent application (title page) published  Effective date of the event=1994-12-07     Event publication date=1998-12-02  Event code=EP/RAP2  Event type=Change of name or address  Event type=Reassignment  Transfer of rights of an EP granted patent Patentinhaber uebertragung (korr.)    Event publication date=1998-12-02  Event code=EP/RAP2  Event type=Change of name or address  Event type=Reassignment  Transfer of rights of an EP granted patent Patentinhaber uebertragung (korr.)    Event publication date=1998-12-16  Event code=EP/K2C1  Event type=Corrections  Correction of patent specification (title page) published  Effective date of the event=1998-10-28     Event publication date=1999-10-20  Event code=EP/26N  Event indicator=Pos  Event type=No opposition filed  Event type=Event indicating In Force  No opposition filed Kein einspruch eingelegt    Event publication date=2013-10-18  Event code=EP/EEDX  Event indicator=Neg  Event type=Event indicating Not In Force  Patent has expired MEMBER STATE LEGAL DETAILS FOR AT172711  Actual or expected expiration date=2013-10-18    Legal state=DEAD    Status=EXPIRED   Corresponding cc:  Designated or member state=AT Corresponding appl: AT93923035  Application date in the designated or member state=1993-10-18   Application number in the designated or member state=1993AT-0923035T Corresponding cc:  Designated or member state=AT Corresponding pat: AT172711  Publication stage code in the designated or member state=T  Publication date in the designated or member state=1998-11-15   Publication number in the designated or member state=ATE172711    Event publication date=1998-10-28  Event code=EP/REF  Event type=Entry into national phase  Corresponds to: Corresponding cc:  Designated or member state=AT     Event publication date=1999-12-15  Event code=EP/REG  Event code=AT/UEP  Event indicator=Pos  Event type=Examination events  Event type=Entry into national phase  Reference to a national code Publication of translation of european patent specification Uebersetzung der europaeischen patentschrift ausgegeben Corresponding cc:  Designated or member state=AT     Event publication date=2001-12-15  Event code=EP/REG  Event code=AT/EEFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change of the company name Firmenaenderung Corresponding cc:  Designated or member state=AT     Event publication date=2004-07-15  Event code=EP/REG  Event code=AT/EEFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change of the company name Firmenaenderung Corresponding cc:  Designated or member state=AT     Event publication date=2006-05-15  Event code=EP/REG  Event code=AT/EEIH  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person of patent owner Aenderung in der person des inhabers Corresponding cc:  Designated or member state=AT     Event publication date=2011-05-15  Event code=EP/REG  Event code=AT/EEIH  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person of patent owner Aenderung in der person des inhabers Corresponding cc:  Designated or member state=AT     Event publication date=2011-08-15  Event code=EP/REG  Event code=AT/ESZA  Event indicator=Pos  Event type=Extension of term of duration of protection  Event type=Restitution or restoration  Reference to a national code Application filed for a certificate of protection (e-series) Anmeldung eines schutzzertifikates (e-serie)  SPC FILING DATE:  FDD=2011-06-30  PRODUCT NAME: FINGOLIMOD, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON  Corresponding cc:  Designated or member state=AT    Supplementary Protection certificate number=SZ 17/2011     Event publication date=2012-03-15  Event code=EP/REG  Event code=AT/EEZF  Event indicator=Pos  Event type=Extension of term of duration of protection  Event type=Restitution or restoration  Reference to a national code Grant for a certificate of protection (e-series) Erteilung eines schutzzertifikates (e-serie)  SPC FILING DATE:  FDD=2011-06-30   Effective date of the event=2012-01-11  EXTENDED:  Extension date=2018-10-18  Corresponding cc:  Designated or member state=AT    Supplementary Protection certificate number=SZ 17/2011     Event publication date=2012-10-29  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-10-29     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=AT     Event publication date=2013-12-15  Event code=EP/REG  Event code=AT/MK07  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Expiry Loeschung wegen zeitablaufs Corresponding cc:  Designated or member state=AT   Effective date of the event=2013-10-18  MEMBER STATE LEGAL DETAILS FOR BE  Actual or expected expiration date=2013-10-18    Legal state=DEAD    Status=EXPIRED   Corresponding cc:  Designated or member state=BE     Event publication date=2007-12-31  Event code=EP/BECN  Event type=Change of name or address  Event type=Reassignment  BE: Change of holder's name BE: Changement de nom de titulaire de brevet Corresponding cc:  Designated or member state=BE   Effective date of the event=2005-12-05     Event publication date=2007-12-31  Event code=EP/BECN  Event type=Change of name or address  Event type=Reassignment  BE: Change of holder's name BE: Changement de nom de titulaire de brevet Corresponding cc:  Designated or member state=BE   Effective date of the event=2005-12-05     Event publication date=2011-03-31  Event code=EP/BECH  Event type=Change of name or address  Event type=Reassignment  BE: Change of holder BE: Changement de titulaire de brevet Corresponding cc:  Designated or member state=BE   Effective date of the event=2011-03-31     Event publication date=2011-03-31  Event code=EP/BECH  Event type=Change of name or address  Event type=Reassignment  BE: Change of holder BE: Changement de titulaire de brevet Corresponding cc:  Designated or member state=BE   Effective date of the event=2011-03-31     Event publication date=2012-10-30  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-10-30     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=BE     Event publication date=2013-10-31  Event code=EP/BE20  Event indicator=Neg  Event type=Event indicating Not In Force  BE: Patent expired BE: Brevet echu Corresponding cc:  Designated or member state=BE   Effective date of the event=2013-10-18     Event publication date=2013-10-31  Event code=EP/BE20  Event indicator=Neg  Event type=Event indicating Not In Force  BE: Patent expired BE: Brevet echu Corresponding cc:  Designated or member state=BE   Effective date of the event=2013-10-18  MEMBER STATE LEGAL DETAILS FOR CH  Actual or expected expiration date=2013-10-31    Legal state=DEAD    Status=EXPIRED   Corresponding cc:  Designated or member state=CH     Event publication date=1998-10-30  Event code=EP/REG  Event code=CH/EP  Event indicator=Pos  Event type=Entry into national phase  Reference to a national code Entry in the national phase Eintritt in die nationale phase Corresponding cc:  Designated or member state=CH     Event publication date=1999-01-29  Event code=EP/REG  Event code=CH/NV  Event type=Change of name or address  Reference to a national code New agent Neuer vertreter/nouveaux mandataires/nuovi mandatari Corresponding cc:  Designated or member state=CH     Event publication date=2001-04-12  Event code=EP/REG  Event code=CH/PFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Name/firm changed Namens-/firmenaenderung Corresponding cc:  Designated or member state=CH  YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. TAITO CO., LTD. TRANSFER- TAITO CO., LTD. WELFIDE CORPORATION     Event publication date=2002-12-13  Event code=EP/REG  Event code=CH/PFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Name/firm changed Namens-/firmenaenderung Corresponding cc:  Designated or member state=CH  TAITO CO., LTD. WELFIDE CORPORATION TRANSFER- TAITO CO., LTD. MITSUBISHI PHARMA CORPORATION     Event publication date=2005-12-15  Event code=EP/REG  Event code=CH/PFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Name/firm changed Namens-/firmenaenderung Corresponding cc:  Designated or member state=CH  MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ SHIN MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP) -TRANSFER TO- MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP)     Event publication date=2005-12-15  Event code=EP/REG  Event code=CH/PUEA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Assignment of the share Uebertragung des anteiles Corresponding cc:  Designated or member state=CH  TAITO CO., LTD.#7-5, NIHONBASHI-ODENMACHO, CHUO-KU#TOKYO 103 (JP)  $ MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP) -TRANSFER TO- MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ SHIN MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP)     Event publication date=2008-06-25  Event code=EP/REG  Event code=CH/PFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Name/firm changed Namens-/firmenaenderung Corresponding cc:  Designated or member state=CH  MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP) -TRANSFER TO- MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP)     Event publication date=2011-03-15  Event code=EP/REG  Event code=CH/PFA  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Name/firm changed Namens-/firmenaenderung Corresponding cc:  Designated or member state=CH  MITSUBISHI PHARMA CORPORATION#6-9, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA-SHI, OSAKA 541-0046 (JP)  $ MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP) -TRANSFER TO- MITSUI SUGAR CO., LTD.#8-2, NIHONBASHI HONCHO 2-CHOME CHUO-KU#TOKYO (JP)  $ MITSUBISHI TANABE PHARMA CORPORATION#2-6-18, KITAHAMA CHUO-KU OSAKA-SHI#OSAKA 541-8505 (JP)     Event publication date=2011-07-15  Event code=EP/REG  Event code=CH/SPCF  Event type=Extension of term of duration of protection  Reference to a national code Supplementary protection certificate filed Zertifikatsanmeldung Corresponding cc:  Designated or member state=CH  PRODUCT NAME: FINGOLIMOD  REGISTRATION NUMBER/DATE: SWISSMEDIC 60916 03.01.2011     Event publication date=2012-10-30  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-10-30     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=CH     Event publication date=2013-09-30  Event code=EP/REG  Event code=CH/SPCG  Event type=Extension of term of duration of protection  Event type=Corrections  Reference to a national code Supplementary protection certificate granted Zertifikatserteilung EXTENDED:  Extension date=2018-10-17  PRODUCT NAME: 2-AMINO-1, 3- PROPANDIOLVERBINDUNG UND IMMUNOSUPPRESSIUM, FINGOLIMOD  REGISTRATION NO/DATE: SWISSMEDIC 60916 20110103  Corresponding cc:  Designated or member state=CH    Supplementary Protection certificate number=C00627406/01     Event publication date=2013-10-31  Event code=EP/REG  Event code=CH/PL  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Patent ceased Loeschung/radiation/radiazion Corresponding cc:  Designated or member state=CH     Event publication date=2014-07-15  Event code=EP/REG  Event code=CH/SPCP  Event type=Extension of term of duration of protection  Reference to a national code Certificates - modification of firm Zertifikate - firmenaenderung FORMER REPRESENTATIVE: BOHEST AG, CH  Corresponding cc:  Designated or member state=CH    Supplementary Protection certificate number=C00627406/01  MEMBER STATE LEGAL DETAILS FOR DE69321823  Actual or expected expiration date=2013-10-18    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE Corresponding appl: DE69321823  Application date in the designated or member state=1993-10-18   Application number in the designated or member state=1993DE-6021823 Corresponding cc:  Designated or member state=DE Corresponding pat: DE69321823  Publication stage code in the designated or member state=D1  Publication date in the designated or member state=1998-12-03   Publication number in the designated or member state=DE69321823    Event publication date=1998-12-03  Event code=EP/REF  Event type=Entry into national phase  Corresponds to: Corresponding cc:  Designated or member state=DE     Event publication date=1999-11-25  Event code=EP/REG  Event code=DE/8364  Event indicator=Pos  Event type=No opposition filed  Reference to a national code No opposition during term of opposition Einspruchsfrist abgelaufen ohne dass einspruch erhoben wurde Corresponding cc:  Designated or member state=DE     Event publication date=2001-05-23  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2003-02-20  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2003-02-20  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2006-02-16  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2006-02-16  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/R081  Event type=Examination events  Event type=Reassignment  Reference to a national code Change of applicant/patentee Aenderung des anmelders/inhabers Corresponding cc:  Designated or member state=DE   Effective date of the event=2011-03-02  FORMER OWNER: MITSUBISHI PHARMA CORP., MITSUI SUGAR CO., LTD., , JP     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/R081  Event type=Examination events  Event type=Reassignment  Reference to a national code Change of applicant/patentee Aenderung des anmelders/inhabers Corresponding cc:  Designated or member state=DE   Effective date of the event=2011-03-02  FORMER OWNER: MITSUBISHI PHARMA CORP., MITSUI SUGAR CO., LTD., , JP     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/R081  Event type=Examination events  Event type=Reassignment  Reference to a national code Change of applicant/patentee Aenderung des anmelders/inhabers Corresponding cc:  Designated or member state=DE   Effective date of the event=2011-03-02  FORMER OWNERS: MITSUBISHI PHARMA CORP., OSAKA, JP  MITSUI SUGAR CO., LTD., 103-8423 TOKYO, CHUO-KU, JP     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/R081  Event type=Examination events  Event type=Reassignment  Reference to a national code Change of applicant/patentee Aenderung des anmelders/inhabers Corresponding cc:  Designated or member state=DE   Effective date of the event=2011-03-02  FORMER OWNERS: MITSUBISHI PHARMA CORP., OSAKA, JP  MITSUI SUGAR CO., LTD., 103-8423 TOKYO, CHUO-KU, JP     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2011-05-05  Event code=EP/REG  Event code=DE/8327  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change in the person/name/address of the patent owner Aenderung in person, namen oder wohnort des patentinhabers Corresponding cc:  Designated or member state=DE     Event publication date=2011-10-20  Event code=EP/REG  Event code=DE/R065  Event indicator=Pos  Event type=Extension of term of duration of protection  Reference to a national code Request for grant of supplementary protection certificate validly filed Antrag auf erteilung eines ergaenzenden schutzzertifikats wirksam gestellt  SPC FILING DATE:  FDD=2011-06-30   Effective date of the event=2011-08-29  EXPIRES:  Expiration date=2013-10-19   EXTENDED:  Extension date=2018-10-18  PRODUCT NAME: FINGOLIMOD ODER EIN SALZ HIERVON, INSBESONDERE FINGOLIMOD-HYDROCHLORID  REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317  Corresponding cc:  Designated or member state=DE    Supplementary Protection certificate number=122011100012     Event publication date=2012-11-20  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-11-20     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=DE     Event publication date=2013-05-27  Event code=EP/REG  Event code=DE/R067  Event indicator=Pos  Event type=Examination events  Reference to a national code Examining division decision granting supplementary protection certificate Erteilungsbeschluss des ergaenzenden schutzzertifikats durch patentabteilung  FILING DATE:  FDD=2011-06-30  EXPIRES:  Expiration date=2013-10-19   EXTENDED:  Extension date=2018-10-18  PRODUCT NAME: FINGOLIMOD ODER EIN SALZ HIERVON, INSBESONDERE FINGOLIMOD-HYDROCHLORID  REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317  Corresponding cc:  Designated or member state=DE    Supplementary Protection certificate number=122011100012     Event publication date=2013-09-26  Event code=EP/REG  Event code=DE/R069  Event indicator=Pos  Event type=Examination events  Reference to a national code Supplementary protection certificate granted Ergaenzendes schutzzertifikat erteilt  FILING DATE:  FDD=2011-06-30   Effective date of the event=2013-07-04  EXPIRES:  Expiration date=2013-10-19   EXTENDED:  Extension date=2018-10-18  PRODUCT NAME: FINGOLIMOD ODER EIN SALZ HIERVON, INSBESONDERE FINGOLIMOD-HYDROCHLORID  REGISTRATION NO/DATE: EU/1/11/677/001-004 20110317  Corresponding cc:  Designated or member state=DE    Supplementary Protection certificate number=122011100012     Event publication date=2013-10-18  Event code=EP/REG  Event code=DE/R071  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Expiry of right Schutzrecht durch zeitablauf erloschen Corresponding cc:  Designated or member state=DE     Event publication date=2013-10-19  Event code=EP/REG  Event code=DE/R071  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Expiry of right Schutzrecht durch zeitablauf erloschen Corresponding cc:  Designated or member state=DE     Event publication date=2014-01-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF EXPIRATION OF PROTECTION  Corresponding cc:  Designated or member state=DE  MEMBER STATE LEGAL DETAILS FOR DK0627406  Actual or expected expiration date=2013-10-18    Legal state=DEAD    Status=EXPIRED   Corresponding cc:  Designated or member state=DK Corresponding appl: DK93923035  Application date in the designated or member state=1993-10-18   Application number in the designated or member state=1993DK-0923035 Corresponding cc:  Designated or member state=DK Corresponding pat: DK0627406  Publication stage code in the designated or member state=T3  Publication date in the designated or member state=1999-07-12   Publication number in the designated or member state=DK-627406T    Event publication date=1999-07-12  Event code=EP/REG  Event code=DK/T3  Event indicator=Pos  Event type=Event indicating In Force  Reference to a national code Translation of EP patent Corresponding cc:  Designated or member state=DK     Event publication date=2011-08-22  Event code=EP/REG  Event code=DK/CTFF  Event type=Extension of term of duration of protection  Reference to a national code Supplementary protection certificate filed Ansoegning om supplerende beskyttelsescertifikat indleveret  SPC FILING DATE:  FDD=2011-06-30  EXPIRES:  Expiration date=2018-10-18  Corresponding cc:  Designated or member state=DK    Supplementary Protection certificate number=CA 2011 00015     Event publication date=2011-08-22  Event code=EP/REG  Event code=DK/CTFG  Event indicator=Pos  Event type=Extension of term of duration of protection  Event type=Restitution or restoration  Reference to a national code Supplementary protection certificate issued Supplerende beskyttelsescertifikat (SPC) meddelt  SPC FILING DATE:  FDD=2011-06-30  PRODUCT NAME: FINGOLIMOD, HERUNDER FINGOLIMOD HYDROCHLORID  Corresponding cc:  Designated or member state=DK    Supplementary Protection certificate number=CA 2011 00015     Event publication date=2012-10-30  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-10-30     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=DK     Event publication date=2013-10-21  Event code=EP/REG  Event code=DK/EUP  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Patent expired Patentet udloebet Corresponding cc:  Designated or member state=DK   Effective date of the event=2013-10-18  MEMBER STATE LEGAL DETAILS FOR ES2126658  Actual or expected expiration date=2014-11-20    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=ES Corresponding appl: ES93923035  Application date in the designated or member state=1993-10-18   Application number in the designated or member state=1993ES-0923035T Corresponding cc:  Designated or member state=ES Corresponding pat: ES2126658  Publication stage code in the designated or member state=T3  Publication date in the designated or member state=1999-04-01   Publication number in the designated or member state=ES2126658    Event publication date=1999-04-01  Event code=EP/REG  Event code=ES/FG2A  Event indicator=Pos  Event type=Event indicating In Force  Reference to a national code Definitive protection Proteccion definitiva Corresponding cc:  Designated or member state=ES     Event publication date=2001-04-16  Event code=EP/REG  Event code=ES/PC2A  Event indicator=Pos  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Transfer granted Transmision concedida Corresponding cc:  Designated or member state=ES     Event publication date=2006-05-16  Event code=EP/REG  Event code=ES/PC2A  Event indicator=Pos  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Transfer granted Transmision concedida Corresponding cc:  Designated or member state=ES     Event publication date=2011-06-08  Event code=EP/REG  Event code=ES/PC2A  Event indicator=Pos  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Transfer granted Transmision concedida Corresponding cc:  Designated or member state=ES   Effective date of the event=2011-05-27     Event publication date=2012-10-18  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2012-10-18     Year of payment of annual fees=20  Corresponding cc:  Designated or member state=ES     Event publication date=2014-11-20  Event code=EP/REG  Event code=ES/FD2A  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Announcement of lapse in spain Ep-patente caducidades Corresponding cc:  Designated or member state=ES   Effective date of the event=2014-11-20     Event publication date=2015-01-30  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF EXPIRATION OF PROTECTION  Corresponding cc:  Designated or member state=ES  MEMBER STATE LEGAL DETAILS FOR FR  Actual or expected expiration date=2018-10-17    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=FR     Event publication date=1999-02-12  Event code=EP/ET  Event indicator=Pos  Event type=Event indicating In Force  FR: Translation filed FR: Traduction a ete remise Corresponding cc:  Designated or member state=FR     Event publication date=2001-06-22  Event code=EP/REG  Event code=FR/CD  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change of name or company name Changement de nom de denomination Corresponding cc:  Designated or member state=FR     Event publication date=2004-02-06  Event code=EP/REG  Event code=FR/CD  Event type=Change of name or address  Event type=Reassignment  Reference to a national code Change of name or company name Changement de nom de denomination Corresponding cc:  Designated or member state=FR     Event publication date=2006-03-10  Event code=EP/REG  Event code=FR/CD  Event type=Change of name or address  Event type=Reass(...)
专利类型码
A1A4B1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部